The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Developments in serplulimab for first line extensive-stage SCLC
Francesco Grossi, MD, University of Insubria, Varese, Italy, comments on emerging chemo-immunotherapy data for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), highlighting the promising results of serplulimab. The novel anti-PD-1 agent demonstrated a significant improvement in median overall survival compared to chemotherapy in clinical trials, making it a valuable addition to the treatment landscape. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
